drugset / Trial / NCT06074484
A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
Phase 2
Unknown
36 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shanxi Province Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with AK104 in perioperative treatment of muscle-invasive bladder cancer.
Timeline
- Start
- 2023-09-10
- Primary completion
- 2024-08-10
- Completion
- 2025-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |